Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIORITI: Adjuvant Triptorelin in High Risk Prostate Cancer
NCT01753297Phase 4Completed
- Sponsor
- Ipsen
- Start
- Dec 2012
- Primary completion
- Sep 2019
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of triptorelin in prostate cancer (PCa), sponsored by Ipsen. Started Dec 2012; status: completed.
02
Drugs
triptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01753297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01753297.